Researchers and commercial vendors highlighted new data and clinical utility, but also discussed challenges in validating and establishing liquid biopsy diagnostics.
Through targeted sequencing on tumors from several biliary tract subtypes, researchers are uncovering mutations of potential treatment or prognostic relevance.
Researchers presenting at ASCO demonstrated the 100-gene panel test plus targeted therapy leads to better outcomes and lower cost than standard chemotherapy.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
Leerink gave the firm an "Outperform" rating with an $18 price target while Canaccord gave it a "Buy" rating with a $17 price target.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.
In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.